- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02349568
The Cost Effectiveness of Endoscopic Ultrasound ( EUS ) Based Strategy in Diagnosis of Common Bile Duct Stones
The Cost Effectiveness Between EUS-based Strategy Versus Endoscopic Retrograde Cholangiopancreatography ( ERCP )-Based Strategy in Diagnosis of Common Bile Duct Stones in Patients With Intermediate Risk: a Study in Developing Country.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Multiple reports showed the efficacy of EUS comparable to ERCP in the diagnosis of CBD stone. The EUS-based strategy has provided the cost saving in diagnosis of CBD stone in patients with intermediate risk in previous studies in western population. There were multiple parameters involved the cost effectiveness analysis included cost of ERCP, cost of EUS, prevalence of CBD stones, the sensitivity and specificity of EUS and the rate of complications related to EUS and ERCP. These parameter may vary from center to center and from region to region.
Aims: To assess the cost effectiveness of EUS based strategy versus ERCP based strategy in diagnosis of CBD stones in patients with intermediate risk in a developing country.
Method : A prospective study in 141 patients with suspected CBD stones based on clinical, biochemical and imaging by trans-abdominal ultrasonography or computed abdominal tomography. All patients underwent EUS. All patients with high risk for CBD stone underwent ERCP after the EUS. For patients with intermediate risk for CBD stone, ERCP's were done at the discretion of the attending physicians. For patients with ERCP done, the diagnosis of CBD stone was confirmed by ERCP demonstration of CBD stone. In patients with intermediate risk without ERCP done, clinical follow up to assess biliary symptoms and liver function test as surrogated markers for CBD stone at 3 months interval for one year were done. The false negative rate in patients with EUS and ERCP done in this study was used to estimate the false negative rate in patients in clinical surrogated group.
Definition: High risk of CBD stones was defined when CBD stone was detected by US/CT or dilated duct with abnormal liver function test ( LFT ). Intermediate risk of CBD stones was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
Cost analysis :The cost of making diagnosis of CBD stone excluding all costs of treatment was analyzed. The cost of all patients with suspected CBD stones undergoing ERCP was calculated and compared with the strategy of EUS follow by ERCP. The cost was evaluated by (1) mean costs of EUS and ERCP based on the actual cost in our center which included costs of medical staffs, disposable materials, drugs, equipment amortization and maintenance. (2) cost associated with complications induced by the procedure.
Statistical analysis: Test performance of the endoscopic ultrasound in diagnosis of CBD stones was analyzed with two by two tables. The sensitivity, specificity, positive and negative predictive values were calculated.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Songkhla
-
Hatyai, Songkhla, Thailand, 90110
- NKC Institues of Gastroenterology and Hepatology, Prince of Songkla University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- history of biliary pain or recent cholangitis
- acute pancreatitis
- abnormal liver function test
- dilatation of CBD and or CBD stone detected by trans-abdominal ultrasound and or computed tomography.
Exclusion Criteria:
- unstable hemodynamics
- severe coagulopathy
- refusal to participate
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
High risk group
High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
|
Patients with high risk underwent EUS examination under conscious sedation.
EUS was examined from second part of duodenum up to duodenal bulb.
All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session.
The ERCPs were performed in standard manner.
All patients were contacted by phone on day 1, 3 and 30 after the procedure.
Other Names:
|
Intermediate risk group
Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
|
Patients with intermediate risk underwent EUS examination under conscious sedation.
EUS was examined from second part of duodenum up to duodenal bulb.
ERCPs were done at the discretion of the attending physicians.
The ERCPs were performed in standard manner.
The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The cost of making diagnosis of CBD stone
Time Frame: within 12 months after EUS
|
The cost of making diagnosis of CBD stone will be measured as the difference in the cost of all patients undergoing ERCP and ERCP follow by EUS intervention.
The cost was evaluated by (1) mean costs of EUS and ERCP based on the actual cost in our center which included costs of medical staffs, disposable materials, drugs, equipment amortization and maintenance.
(2) costs associated with complications induced by the procedure.
|
within 12 months after EUS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The accuracy of EUS in diagnosis of CBD stone
Time Frame: within 12 months after EUS
|
This will be measured as proportion of patients who encounter a correctly diagnosis of CBD stone by EUS.
Positive EUS finding was confirmed by ERCP.
Negative EUS finding was confirmed by ERCP or absence of symptoms for 12 months.
|
within 12 months after EUS
|
The safety of EUS and ERCP procedure
Time Frame: within 1 months
|
This will be measured as proportion of patients who encounter a procedural complication (%) during EUS and ERCP that includes pancreatitis, perforation or hemorrhage
|
within 1 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bancha Ovartlarnporn, MD, NKC Institue of Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkla, Thailand.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC-55-066-21-1-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Bile Duct Calculi
-
Gujranwala medical college District Headquarters...RecruitingCommon Bile Duct Diseases | Common Bile Duct Calculi | Common Bile Duct Stricture | Common Bile Duct Neoplasms | Common Bile Duct DilatationPakistan
-
First People's Hospital of HangzhouCompletedCholedocholithiasis | Common Bile Duct CalculiChina
-
Hospital Universitario Dr. Jose E. GonzalezUnknownCommon Bile Duct CalculiMexico
-
Kepler University HospitalCompletedCholelithiasis, Common Bile DuctAustria
-
University of Sao Paulo General HospitalBoston Scientific CorporationUnknownCholedocholithiasis | Common Bile Duct GallstonesBrazil
-
Mansoura UniversityCompletedCommon Bile Duct Stones.Egypt
-
Hospital del Río HortegaHospital Universitario Ramon y Cajal; Hospital General Universitario de AlicanteRecruitingCholedocholithiasis | Bile Duct; Obstruction, With CalculusSpain
-
Air Force Military Medical University, ChinaRecruitingCholedocholithiasis | Intrahepatic Bile Duct StoneChina
-
Karolinska InstitutetErsta Hospital, SwedenCompletedCommon Bile Duct Stone
Clinical Trials on High risk group
-
University Health Network, TorontoRecruitingAnal Squamous Cell CarcinomaCanada
-
King's College LondonUK Research and InnovationNot yet recruiting
-
University of Wisconsin, MadisonWisconsin Partnership ProgramRecruitingStroke | AtherosclerosisUnited States
-
Centre Leon BerardCompletedColorectal Cancer PreventionFrance
-
Lawson Health Research InstituteRecruiting
-
Rigshospitalet, DenmarkHvidovre University Hospital; Bispebjerg Hospital; The Novo Nordic Foundation; Aalborg... and other collaboratorsRecruitingPatient Satisfaction | Hip | Knee | Fast-track Surgery | Enhanced Recovery After Surgery | Perioperative Medicine | Ambulatory Surgical Procedures | Perioperative/Postoperative ComplicationsDenmark
-
Hospital Departamental de VillavicencioCooperative University of ColombiaRecruiting
-
Cook Group IncorporatedCompletedAbdominal Aortic Aneurysm
-
Peking Union Medical College HospitalXuanwu Hospital, Beijing; Beijing HospitalUnknown
-
Johns Hopkins UniversityWithdrawnEmergencies | Risk Reduction | Comorbidities and Coexisting ConditionsUnited States